Jazz Pharmaceuticals (JAZZ) EBITDA Margin Growth (3y) (2013 - 2026)

Jazz Pharmaceuticals (JAZZ) EBITDA Margin Growth (3y) (2013 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin Growth (3y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 9,942.00
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 530.00
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -1,211.00
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn -623.00
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Jazz Pharmaceuticals 15.75 Bn 13.91 Bn 934.80 Mn 1,737.00

Historic Data

Download Data
DateValue
Mar 31, 2026 1,737.00
Dec 31, 2025 4,834.00
Sep 30, 2025 247.00
Jun 30, 2025 -7,481.00
Mar 31, 2025 -1,699.00
Dec 31, 2024 1,202.00
Sep 30, 2024 2,128.00
Jun 30, 2024 2,874.00
Mar 31, 2024 -1,934.00
Dec 31, 2023 -1,395.00
Sep 30, 2023 -1,492.00
Jun 30, 2023 -1,876.00
Mar 31, 2023 4,959.00
Dec 31, 2022 -3,762.00
Sep 30, 2022 -2,212.00
Jun 30, 2022 -2,908.00
Mar 31, 2022 -1,556.00
Dec 31, 2021 -3,333.00
Sep 30, 2021 -3,683.00
Jun 30, 2021 -3,987.00